Irsamla

Vortioxetine, the active ingredient in Irsamla, is a serotonin modulator and stimulator presented as an oral tablet for oral use. It treats major depressive disorder in adult patients. GNH USA supplies Irsamla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irsamla, a serotonin modulator and stimulator, is indicated for depressive disorders.

Major depressive disorder: reduces depressive symptoms and improves functional outcomes in adult patients.

Common Side Effects: - Nausea - Headache - Dizziness - Constipation - Dry mouth - Decreased sexual desire

Serious or Rare Side Effects: - Serotonin syndrome (fever, agitation, hyperreflexia) - Suicidal thoughts or behavior, especially in young adults - Severe hyponatremia (low blood sodium) - Allergic reactions (rash, swelling, difficulty breathing) - QT interval prolongation on ECG

Before initiating therapy, consider the following precautions: - Assess for suicidal ideation: monitor mood changes closely. - Evaluate for serotonin syndrome: avoid concurrent serotonergic drugs. - Review hepatic function: dose adjustment may be needed in severe liver impairment. - Caution in bipolar disorder: risk of mood switching. - Avoid abrupt discontinuation: taper under medical supervision. - Store at ambient temperature: keep in the original pack, protect from moisture.

Vortioxetine may interact with several medication classes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Other serotonergic agents (SSRIs, SNRIs, triptans, linezolid): additive serotonin effects. - St. John’s wort: increased serotonergic activity.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, quinidine): may raise vortioxetine levels. - NSAIDs: heightened risk of bleeding. - Antihypertensives: possible additive blood pressure lowering.